Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nm-nOMV SARS-CoV-2 Spike vaccine
- Development stage
- Unknown
- Lead developer
- Intravacc
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Nm-nOMV SARS-CoV-2 Spike vaccine (also known as Avacc 10) is an intranasal vaccine candidate developed by Intravacc and AdJane. It consists of native outer membrane vesicles (nOMVs) derived from a genetically detoxified *Neisseria meningitidis* serogroup B strain combined with a recombinant SARS-CoV-2 Spike protein antigen (manufactured by ExcellGene). The vaccine is designed to induce both systemic and mucosal immune responses, particularly nasal IgA, to prevent SARS-CoV-2 infection and block transmission at the mucosal entry point. In a Phase I clinical trial, the vaccine was shown to be safe, well-tolerated, and immunogenic in healthy adults.
- Other names
- COVID 2019 vaccine - IntravaccCOVID2019 vaccine - IntravaccCOVID-2019 vaccine - IntravaccCovOMVCovOMV - IntravaccNm-nOMV SARS-CoV-2 Spike vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)SARS-CoV-2 spike
Beyond the preview
Go deeper on Nm-nOMV SARS-CoV-2 Spike vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nm-nOMV SARS-CoV-2 Spike vaccine.